Scarica l'app Stockscreener
18.86
1.45%
0.27
Pre-mercato:
18.90
0.04
+0.21%
Precedente Chiudi:
$18.59
Aprire:
$18.82
Volume 24 ore:
2.62M
Relative Volume:
0.86
Capitalizzazione di mercato:
$60.23B
Reddito:
$29.91B
Utile/perdita netta:
$1.30B
Rapporto P/E:
46.50
EPS:
0.4056
Flusso di cassa netto:
$3.49B
1 W Prestazione:
-0.26%
1M Prestazione:
+2.78%
6M Prestazione:
+3.12%
1 anno Prestazione:
+28.74%
Intervallo 1D:
$18.77
$18.91
Intervallo di 1 settimana:
$18.51
$19.05
Portata 52W:
$12.99
$19.10
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, VTRS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | Ripresa | Morgan Stanley | Overweight |
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr Reddy's Laboratories stock gains attention on QDENGA vaccine deal - ad-hoc-news.de
NY stocks mixed, Dow falls for first time in 3 days on rate hike concerns - finance.biggo.com
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
SGIOY Stock Price, Quote & News - syfe.com
Organon & Co. (OGN) Peer Comparison – Compare with Others - Value Research
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - Value Research
Protagonist Therapeutics receives FDA approval for polycythemia vera drug By Investing.com - Investing.com India
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneHigh Volume Stocks - careplusvn.com
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelBPI Bull Correction - vinanet.vn
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - grandviewresearch.com
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.56%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):